(七)演講主題 : 高惡性轉移性乳癌的治療新策略

參考文獻:

1. NEJM 2011;344:787-792
2. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.  Japanese journal of clinical oncology.  2012;42(3), 161-167.
3. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line
4. chemotherapy for metastatic breast cancer patients. Ann Oncol 2012;23: 618e24.
5. A prognostic factor (pf) index for overall survival in a Her2-negative endocrine-resistant metastatic breast cancer (mbc) population: analysis from the ATHENA trial [abstract 555]. 2013 ASCO Annual Meeting
6. Features of aggressive breast cancer.Breast. 2015 Oct;24(5):594-600
7. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 2001;12:231e7
8. Construction and validation of a practical prognostic index for patients with metastatic breast cancer.
9. J Clin Oncol 1998;16:2401e8
10. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol. 2015 Apr;22(2):e51-60
11. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol. 2016 Sep;27(9):1725-32.

陳駿逸醫師目前擔任癌症中醫與西醫臨床治療醫師，著有”擊退癌疲憊 醫師該告訴你的癌後養生術”(康健出版)，專職中西醫結合癌症治療與癌友關懷之公益活動，同時熱心致力於正確癌症照護資訊之推廣與傳遞，其所創建之台中市全方位癌症關懷協會(http://www.cancerinfotw.org )，乃是專業照護人員、社會賢達貢獻所學，所建構的癌症診療與照護資訊平臺。

此處文章乃是醫療照護資訊的整理，請勿引據文章內容自行採取醫療決定；如有臨床治療之需求，建議還是應該尋求專業醫療人員的協助。如有任何謬誤或建議，懇請不吝指教。

需要閱覽作者撰寫的更多相關癌症資訊，歡迎前往陳駿逸醫師官網“話聊俱樂部”

http://cancerfree.medicalmap.tw/alonepage.php?id=7